The baseline characteristics of people initiated on an SGLT2i or DPP4i
| SGLT2i (n=21 008) | DPP4i (n=55 481) | |
| Age (years) | 60.4 (9.3) | 63.3 (10.8) |
| Female (n (%)) | 8115 (38.6) | 22 274 (40.1) |
| Duration of diabetes (years) | 9.1 (5.4) | 7.9 (5.4) |
| <5 years (n (%)) | 6089 (29.0) | 21 003 (37.9) |
| 5–10 years (n (%)) | 7296 (34.7) | 19 414 (35.0) |
| >10 years (n (%)) | 7623 (36.3) | 15 064 (27.2) |
| Number of concurrent diabetes medications | 1.7 (0.8) | 1.4 (0.7) |
| HbA1c (% (mmol/mol)) | 78.2 (16.7) | 73.1 (16.6) |
| <8.0 (<64)(n (%)) | 4401 (20.9) | 19 067 (34.4) |
| 8.0–9.5 (64–80) (n (%)) | 8547 (40.7) | 21 665 (39.0) |
| >9.5 (>80) (n (%)) | 8060 (38.4) | 14 749 (26.6) |
| eGFR (mL/min) | 87.9 (15.2) | 82.7 (17.5) |
| 45–<60 mL/min (n (%)) | 890 (4.2) | 6997 (12.6) |
| 60–90 (n (%)) | 9674 (46.0) | 27 245 (49.1) |
| >90 (n (%)) | 10 444 (49.7) | 21 239 (38.3) |
| BMI (kg/m2) | 34.4 (6.7) | 32.7 (6.6) |
| <25 kg/m2 (n (%)) | 946 (4.5) | 5156 (9.3) |
| 25–30 kg/m2 (n (%)) | 4747 (22.6) | 16 040 (28.9) |
| >30 kg/m2 (n (%)) | 15 311 (72.9) | 34 275 (61.8) |
| Previous genital mycosis (n (%)) | ||
| Never | 16 877 (80.3) | 46 663 (84.1) |
| <1 year | 722 (3.4) | 1753 (3.2) |
| 1–5 years | 1363 (6.5) | 2943 (5.3) |
| >5 years | 2046 (9.7) | 4122 (7.4) |
| Corticosteroid use (n (%)) | 2317 (4.2) | 718 (3.4) |
| Oestrogen use (n (%)) | 665 (1.2) | 252 (1.2) |
| Immunomodulator use (n (%)) | 629 (1.1) | 219 (1.0) |
All values shown are mean (SD) unless otherwise stated.
BMI, body mass index; DPP4i, Dipeptidyl peptidase-4 inhibitor; eGFR, estimated glomerular filtration rate; SGTL2, sodium-glucose co-transporter-2.